30.8 C
New York
Saturday, June 6, 2026

Tag: body

newssourceFORcompanyinformationcontent1marketreleases

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

Clinical Amino Acid Profiles Anchor PureHealth Research’s New Natural Peptides Supplements

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today pointed to the growing scientific interest in naturally sourced peptide nutrition for healthy aging...

PureHealth Research Highlights Growing Consumer Interest in Lymphatic Wellness and Botanical Support

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today highlighted the growing consumer interest in lymphatic wellness and the role botanicals may play...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Press release – No. 13 / 2026 

SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver

Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech),...

Pudu Robotics Unveils PuduFM 1.0 and PuduAgent: Defining the Next Era of Humanoid and Embodied AI Systems

Pudu Robotics launches PuduFM 1.0 & PuduAgent, enabling "One Brain, Multiple Embodiments" for scalable service robots across industries.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBody

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers